Business
Pharma Equity Group A/S - Annual Report 2025
25 March 2026 Announcement no. 3 Pharma Equity Group A/S - Annual Report 2025 Pharma Equity Group A/S - Annual Report 2025 – Highlights of the year Today, the Board of Directors of Pharma Equity Group A/S reviewed and approved the Company’s Annual Report for 2025, the key highlights of which are as follows: In 2025, Reponex Pharmaceuticals A/S obtained regulatory approval to initiate a pivotal Phase 2 trial of RNX-011 for the treatment of secondary bacterial peritonitis.In 2025, RNX-051 was furt
About this update from Pharma Equity Group A/s Class A
[{"type":"image","alt":"Pharma Equity Group A/S","displaySize":"","headline":null,"caption":"Pharma Equity Group A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":34,"url":"https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jPpWLNKdrqa99i9B0sGpWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ4/https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c","width":300,"height":34}},"lazy":false},{"type":"text","content":"25 March 2026","length":13,"tagName":"p"},{"type":"text","content":"Announcement no. 3","length":18,"tagName":"p"},{"type":"text","content":"Pharma Equity Group A/S - Annual Report 2025","length":44,"tagName":"p"},{"type":"text","content":"Pharma Equity Group A/S - Annual Report 2025 – Highlights of the year","length":69,"tagName":"p"},{"type":"text","content":"Today, the Board of Directors of Pharma Equity Group A/S reviewed and approved the Company’s Annual Report for 2025, the key highlights of which are as follows:","length":160,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In 2025, Reponex Pharmaceuticals A/S obtained regulatory approval to initiate a pivotal Phase 2 trial of RNX-011 for the treatment of secondary bacterial peritonitis.","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"In 2025, RNX-051 was further advanced through continued development work, further maturation of the formulation and continued dialogue with potential industrial partners. The Company is engaged in advanced and constructive discussions with potential partners regarding RNX-051, and, if progress continues as expected, these discussions are expected to be concluded during the first half of 2026.","length":395,"tagName":"p"}]},{"val":[{"type":"text","content":"In 2025, the Company launched an updated investment strategy aimed at diversifying the portfolio across Pharma and Medical Devices/MedTech, established an Investment Committee and strengthened the Group’s governance framework.","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"In 2025, convertible loans totaling DKK 32.3 million were raised, comprising DKK 6.8 million on 1 April 2025, DKK 5.8 million on 1 July 2025, DKK 10.9 million on 1 October 2025 and DKK 8.8 million on 1 December 2025. Of this amount, DKK 16.4 million...